Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

BioStem Technologies Q3 2026 Results: Net Loss of $11.4M

BioStem Technologies reported a significant decline in revenue to $21.7 million for the nine months ended September 30, 2026, compared to $37.4 million in the prior year, resulting in a net loss from operations of $27.1 million. The company is facing liquidity challenges, including an unpaid $10 million clearance payment due to BioTissue and a substantial decrease in cash from $29.5 million to $971,145 over the nine-month period.

Watch the BioStem Technologies, Inc. earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue7.610.5
Gross profit4.39.3
Profit before tax-11.41.5
Net income-11.40.8
EPS (diluted, $ a share)$-0.64$0.03

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-27.0%
Gross margin56.2%
Operating margin-127.9%
Source

10-Q filed with the SEC, NASDAQ: BSEM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

BioStem Technologies, Inc.: key numbers

Share price
$0.9601Close, Nov 16
Market cap
$18.4M
Shares outstanding
19.18MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from BioStem Technologies, Inc.

All →
4:06 PM ET 8-K
Financial Results

BioStem Technologies Financial Results

BioStem Technologies reported Q3 2026 financial results, highlighting sequential hospital revenue growth to $6.8 million and increased customer penetration. The company raised its full-year 2026 revenue guidance and is finalizing a cost reduction plan to reduce annualized cash operating expenses by $10-$12 million.

Term
Q3 2026

“We grew hospital revenue again this quarter, and importantly, are doing so by adding new accounts and increasing penetration with existing customers. The number of customers buying two or more of our product lines grew 14% from the second quarter. We also completed the final step of our commercial infrastructure build-out, and with in-house production of Neox and Clarix expected to begin in the first half of 2027, we are on track to become a fully vertically integrated company with those product lines.”

Jason Matuszewski, Chair and CEO of BioStem

“With these foundations in place, we are focused on strengthening the balance sheet, raising our gross margin, reducing operating expenses and narrowing our adjusted EBITDA loss as we work toward breakeven.”

Jason Matuszewski, Chair and CEO of BioStem
4:49 PM ET 8-K
Capital Raise

BioStem Technologies Capital Raise of $3M

BioStem Technologies entered into a securities purchase agreement with institutional investors for a $3.0 million private placement of 735,296 shares of common stock. The offering includes Series A and Series B warrants to purchase additional shares at an exercise price of $3.83 per share, which could provide an additional $5.6 million if fully exercised. Proceeds are intended for working capital and general corporate purposes.

Value
$3M
Counterparty
institutional investors
4:16 PM ET 8-K
Other 8-K Filing

BioStem Technologies Other 8-K Filing

BioStem Technologies entered into a $40 million committed equity facility with Roth Principal Investments, allowing the company to sell shares of common stock at its discretion over a 36-month period. The facility provides opportunistic access to capital for working capital and general corporate purposes, though no shares were sold at the time of the filing. Sales are subject to a registration statement being declared effective and a minimum threshold price of $1.00 per share.

Counterparty
Roth Principal Investments, LLC
Term
36 months

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.